Comparison of registration parameters of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in different countries

Abstract

Aim. Conduction of quantitative and qualitative analysis of registration parameters of medications of two groups - angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in Russian Federation compared to those of leading drug regulators.

Methods. The whole list of currently existing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers according to international Anatomical Therapeutic Chemical Classification of drugs was analyzed by quantitative and qualitative characteristics in four national drug regulators: State drug register of the Russian Federation, American drug regulator - Food and Drug Administration, European Medicines Agency, and Australian drug regulator - Therapeutic Goods Administration.

Results. It was found that by the number of registered international nonproprietary names and by the number of trade names in the group of angiotensin converting enzyme inhibitors the leading position is taken by State drug registry of the RF, and in the group of angiotensin II receptor blockers Therapeutic Goods Administration is leading. On the territory of Russian Federation among angiotensin converting enzyme inhibitors, lisinopril, captopril, perindopril and enalapril are registered in the highest numbers of trade names, and among angiotensin II receptor blockers - losartan and valsartan. The example of the best practice is presented by European Medicines Agency with the lowest number of registered international nonproprietary and trade names. The qualitative analysis of registration parameters of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers (accepted indications) revealed that in RF the highest number of indications for both angiotensin converting enzyme inhibitors and angiotensin II receptor blockers is accepted compared to those of the leading drug regulators. The example of the best practice by this criterion is presented by the European regulator - European Medicines Agency. Based on the understanding that all international nonproprietary names in every analyzed pharmacological group are medications of the «me too» category, the decrease of the number of registration positions by national regulator and thorough analysis of evidence of effects are recommended when approving indications.

Conclusion. In the official state drug registry of RF compared to three foreign drug regulators, the highest number of international nonproprietary names and trade names of angiotensin converting enzyme inhibitors are presented as well as indications for both angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.

Keywords

angiotensin converting enzyme inhibitors / angiotensin II receptor blockers / rational use of drugs / regulation of drug circulation

References

[1] Dorovskoy A.V. Segments of the world pharmaceutical market: trends and contradictions in development. BIZNESINFORM. 2014; (9): 34–40. (In Russ.)

[2] Доровской А.В. Сегменты мирового фармацевтического рынка: тенденции и противоречия развития. БIЗНЕСIНФОРМ. 2014; (9): 34-40.

[3] The rational use of drugs — report of the WHO Conference of experts, Nairobi 25–29 November 1985. http://apps.who.int/medicinedocs/en/rn/ abstract/Js17054e (access date: 28.08.2017).

[4] The rational use of drugs - report of the WHO Conference of experts, Nairobi 25-29 November 1985. http://apps.who.int/medicinedocs/en/rn/ abstract/Js17054e (access date: 28.08.2017).

[5] Wirtz V.J., Hogerzeil H.V., Gray A.L. et al. Essential medicines for universal health coverage. Lancet. 2017; 389 (10067): 403–476. DOI: 10.1016/S0140-6736(16)31599-9.

[6] Wirtz V.J., Hogerzeil H.V., Gray A.L. et al. Essential medicines for universal health coverage. Lancet. 2017; 389 (10067): 403-476. DOI: 10.1016/S0140-6736(16)31599-9.

[7] Malichenko V.S. International legal mechanisms ensuring security of medicines circulation. Evraziskiy yuridicheskiy zhurnal. 2014; (10): 71–75. (In Russ.)

[8] Маличенко В.С. Международно-правовые механизмы обеспечения безопасности обращения лекарственных средств. Евразийский юридич. ж. 2014; (10): 71-75.

[9] Sychev D.A. Polipragmaziya v klinicheskoy praktike: problema i resheniya. Uchebnoe posobie. (Polypharmacy in clinical practice: the problem and solutions. Study guide.) Saint Petersburg: TsOP Professiya. 2016; 224 p. (In Russ.)

[10] Сычёв Д.А. Полипрагмазия в клинической практике: проблема и решения. Учебное пособие. СПб.: ЦОП Профессия. 2016; 224 с.

[11] Gotzsche P.K. Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare. London: Radcliffe Publishing; 2013. Russ. Ed.: Gotzsche P.K. Smertel’no opasnye lekarstva i organizovannaya prestupnost’. Kak «bol’shaya farma» korrumpirovala zdravookhranenie. Moscow: EKSMO. 2016; 464 p. (In Russ.)

[12] Гётше П.К. Смертельно опасные лекарства и организованная преступность. Как «большая фарма» коррумпировала здравоохранение. Перевод с англ. Москва: ЭКСМО. 2016; 464 с.

[13] Ziganshina L.E., Niyazov R.R., Ziganshin A.U. The WHO concept of essential medicines and the who ethical criteria for medicinal drug promotion: history and lessons for domestic pharmaceutical sector. Kazanskiy meditsinskiy zhurnal. 2013; 94 (1): 95–100. (In Russ.)

[14] Зиганшина Л.Е., Ниязов Р.Р., Зиганшин А.У. Концепция основных лекарств и этические критерии Всемирной организации здравоохранения продвижения лекарств: история и уроки для развития отечественной фармацевтической отрасли. Казанский мед. ж. 2013; 94 (1): 95-100.

[15] Shaydullina L.Ya. Ratio­nal use of medicines: contribution to the development of health systems. Kazanskiy meditsinskiy zhurnal. 2012; 93 (5): 803–806. (In Russ.)

[16] Шайдуллина Л.Я. Рациональное использование лекарств: вклад в развитие систем здравоохранения. Казанский мед. ж. 2012; 93 (5): 803-806.

[17] Vol’skaya E.A. About pharma­ceutical innovations. Remedium. 2007; (12): 6–10. (In Russ.)

[18] Вольская Е.А. О фармацевтических инновациях. Ремедиум. 2007; (12): 6-10.

[19] Frohlich E.D., Ventura N.O. Hypertension: an atlas of investigation and management. London: Clinical Publishing. 2008; 134 p.

[20] Libby P.P. et al. Braunwald’s heart disease: A textbook of cardiovascular medicine. 8th edition. Philadelphia: Elsevier Science. 2007. Russ. ed.: Bolezni serdtsa po Braunval’du: rukovodstvo po serdechno-sosudistoy meditsine. Ed. by R.G. Oganov. Moscow: Logosfera. 2010; (1): 576 p. (In Russ.)

[21] Либби П. Болезни сердца по Браунвальду: руководство по сердечно-сосудистой медицине. Под ред. П. Либби и др. Пер. с англ., под общ. ред. Р.Г. Оганова. М.: Логосфера. 2010; (1): 576 с.

[22] Belyalov F.I. Klinicheskie rekomendatsii po kardiologii. Posobie dlya vrachey. (Clinical guidelines on cardiology. A manual for doctors.) Ed. by F.I. Belyalov. Irkutsk: RIO GBOU DPO IG-MAPO. 2014; 134 p. (In Russ.)

[23] Белялов Ф.И. Клинические рекомендации по кардиологии. Пособие для врачей. Под ред. Ф.И. Белялова. Иркутск: РИО ГБОУ ДПО ИГ-МАПО. 2014; 134 с.

[24] Chazova I.E., Oshchepkova E.V., Zhernakova Yu.V. et al. Clinical recommendations: diagnosis and treatment of arterial hypertension. Kardiologicheskiy vesthik. 2015; 10 (1): 3–30. (In Russ.)

[25] Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. и др. Клинические рекомендации: диагностика и лечение артериальной гипертонии. Кардиол. вестн. 2015; 10 (1): 3-30.

[26] State Register of Medicines of the Russian Federation. https://grls.rosminzdrav.ru/Default.aspx (access date: 09.10.2017). (In Russ.)

[27] Государственный реестр лекарственных средств РФ. https://grls.rosminzdrav.ru/Default.aspx (дата обращения: 09.10.2017).

[28] Food and Drug Administration. https://www.fda.gov/ (access date: 09.10.2017).

[29] European Medicines Agency. http://www.ema.europa.eu/ema/ (access date: 09.10.2017).

[30] Therapeutic Goods Administration. http://www.tga.gov.au/ (access date: 09.10.2017).

[31] Heran B.S., Wong M.M., Heran I.K., Wright J.M. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst. Rev. 2008; (4): CD003823. DOI: 10.1002/14651858.CD003823.pub2.

[32] Heran B.S., Musini V.M., Bassett K. et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst. Rev. 2012; (4): CD003040. DOI: 10.1002/14651858.CD003040.pub2.

RIGHTS & PERMISSIONS

Garaeva A.F., Ziganshin A.U., Ziganshina L.E.